In most instances, both the glioma and blood samples were obtained and immediately processed in parallel to determine the expression of immune therapeutic targets on the CD11b+ myeloid and the CD3+ T cell population (Figure 1). This evidence concerns the gene ITGAM and central nervous system cancer.